McKesson Corporation’s (MCK) Biologics by McKesson, its independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion for subcutaneous use. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.CAMCEVI was approved by the FDA on May 25, 2021.The availability of the FDA-approv ...